Physician
Endocrinology
Verena Hug
|
|
Give Review
Verena practices Endocrinology. She went to Baylor College of Medicine. Verena is a published doctor as well. She has 54 publications published. The latest was: The clonogenic growth of advanced breast tumour lesions adds no value to that of established clinical prognosticators for survival. Verena Hug accepts Medicare payments and is registered with Medicare.gov.
Publications
- Regulation of insulin receptor gene expression. Cell cycle-mediated effects on insulin receptor mRNA stability.
- Chemosensitivities of human clonogenic breast tumor cells.
- Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate.
- Phase II study of iproplatin in metastatic breast carcinoma.
- Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
- Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors.
- Unusual toxicity of doxorubicin infusion.
- Phase II evaluation of Ly156758 in metastatic breast cancer.
- Cisplatin in combination with continuous infusion vinblastine for refractory breast cancer.
- Chemoresistance is not a cause of the apparent failure of adjuvant chemotherapy in postmenopausal women.
- Clonogenic growth and hormone sensitivity of benign and malignant breast tissues.
- Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
- Chemotherapy and hormonal therapy in combination.
- Mitomycin for treatment of brain parenchymal disease.
- Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer.
- Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.
- Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer.
- Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy.
- Predictors of hormone response for patients with ER-unknown breast tumours.
- Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
- Body weight and breast cancer.
- Sequential cyclic combined hormonal therapy for metastatic breast cancer.
- Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?
- Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.
- Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.
- Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.
- The clonogenic growth of advanced breast tumour lesions adds no value to that of established clinical prognosticators for survival.
- Nuclear protein-binding analysis of a GC-rich insulin-receptor promoter regulatory region.
- The results of modified use of chemotherapy for patients with metastatic breast cancer.
- Dexamethasone mediated stabilization of insulin receptor mRNA.
- Sequence and functional characterization of the terminal exon of the human insulin receptor gene.
- A phase II study of peptichemio in advanced breast cancer.
- [Oral hygiene in the proximal space].
- Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofur...
- The true predictive value of the human tumor stem cell assay: does a workable assay select for treatment responders?
- Normalization of in vitro sensitivity testing of human tumor clonogenic cells.
- Growth factor enhancement of the in vitro stem cell assay.
- Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count.
- Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with...
- Dose-survival curves of cis-platinum, melphalan, and velban in human granulocyte/macrophage progenitor cells.
- Improved culture conditions for clonogenic growth of primary human breast tumours.
- Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium.
- Effect of diethylaminoethyl-dextran on colony formation of human tumor cells in semisolid suspension cultures.
- [Status of the hospital aide within the nursing team].
- Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors.
- Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro.
- Effect of cyclophosphamide on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura.
- Clonogenic in vitro growth and histologic grading of primary human breast tumors.
- The human tumor stem cell assay revisited.
- Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays.
- Effects and interactions of epidermal growth factor, insulin, hydrocortisone, and estradiol on the cloning of human tumor cells.
- In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells.
- Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.
Doctors Specialties
- Endocrinology
Accepted Insurances
Education
-
Baylor College of Medicine -
University of Texas MD Anderson Cancer Center -
University of Bern Faculty of Medicine